|
source DB |
source ID
|
text
|
size
|
updated at |
|
# proj.
|
|
# Ann.
|
updated_at |
| PubMed |
26232222 |
Identification of Genetic Factors that Modify Clinical Onset of Huntington's Disease.
As a Mendelian |
1.03 KB |
2020-02-21 |
|
19 |
|
37 |
2021-01-27
|
| PubMed |
26215578 |
Epiregulin contributes to breast tumorigenesis through regulating matrix metalloproteinase 1 and pro |
2.38 KB |
2020-01-22 |
|
9 |
|
292 |
2021-01-27
|
| PubMed |
26165466 |
Delayed Cell Cycle Progression in STHdh(Q111)/Hdh(Q111) Cells, a Cell Model for Huntington's Disease |
1.45 KB |
2016-01-24 |
|
8 |
|
1,829 |
2021-01-27
|
| PubMed |
26159606 |
Mutations in LRRK2 potentiate age-related impairment of autophagic flux.
Autophagy is thought to pla |
1.09 KB |
2020-01-21 |
|
10 |
|
54 |
2021-01-27
|
| PubMed |
26123485 |
Selective expression of Parkinson's disease-related Leucine-rich repeat kinase 2 G2019S missense mut |
1.83 KB |
2020-01-29 |
|
11 |
|
172 |
2021-01-27
|
| PubMed |
26047474 |
Large expansion of CTG•CAG repeats is exacerbated by MutSβ in human cells.
Trinucleotide repeat expa |
1.46 KB |
2016-01-24 |
|
19 |
|
164 |
2021-01-27
|
| PubMed |
25836420 |
Progressive dopaminergic alterations and mitochondrial abnormalities in LRRK2 G2019S knock-in mice.
|
1.62 KB |
2020-01-21 |
|
9 |
|
85 |
2021-01-27
|
| PubMed |
25830304 |
No dopamine cell loss or changes in cytoskeleton function in transgenic mice expressing physiologica |
1.73 KB |
2020-01-21 |
|
11 |
|
95 |
2021-01-27
|
| PubMed |
25804954 |
Lack of exacerbation of neurodegeneration in a double transgenic mouse model of mutant LRRK2 and tau |
1.71 KB |
2020-01-21 |
|
12 |
|
176 |
2021-01-27
|
| PubMed |
25760041 |
Effects on murine behavior and lifespan of selectively decreasing expression of mutant huntingtin al |
1.53 KB |
2016-01-19 |
|
12 |
|
134 |
2021-01-27
|
